Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.

ABSTRACT:

Background

Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP).

Methods and results

Retrospective cohort study of patients taking QDay lisinopril and losartan who experienced a dose-doubling (index date). A text-processing tool categorized BID and QDay groups at the index date based on administration instructions. We excluded: pregnant/hospice, regimens other than BID/QDay, and without BP measurements -6 months/+12 months of the index date. The most proximal BP measurements -6 months and +2 weeks to 12 months of the index date were used to evaluate BP differences. Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia

SUBMITTER: Derington CG 

PROVIDER: S-EPMC7714357 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature